Indeed, in 2018 in Europe and the USA a fully human immunoglobulin IgG1 monoclonal antibody directed against FGF23 (Burosumab), which prevents FGF23 binding to FGFRs, was approved for the treatment of XLH [55]. Here, FGF23 is linked to X-linked hypophosphatemia.